EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mechanisms of the JNK/p38 MAPK signaling pathway in drug resistance in ovarian cancer

Yu-Ting Ma, Chan Li, Ying Shen, Wan-Hui You, Ming-Xuan Han, Yi-Fan Mu, Feng-Juan Han

Frontiers in Oncology · 24.04.2025 · 15

DOI: 10.3389/fonc.2025.1533352 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 24.04.2025. Verfasst von Yu-Ting Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer (OC) is the most lethal malignancy in the female reproductive system, and chemotherapy drug resistance is the main cause of treatment failure. The Mitogen-Activated Protein Kinases (MAPK) pathway plays a pivotal role in regulating cell proliferation, migration, and invasive capacity in response to extracellular stimuli. This review focuses on the mechanisms and therapeutic strategies related to the JNK/p38 MAPK signaling pathway in OC resistance. The JNK/p38 MAPK pathway plays a dual role in OC chemoresistance. This review examines its role in mediating OC treatment resistance by exploring the mechanisms of action of the JNK/p38 MAPK signaling pathway, particularly its involvement in several key biological processes, including apoptosis, autophagy, DNA damage response, the tumor microenvironment (TME), and drug efflux. Additionally, the review investigates the timing of activation of this pathway and its crosstalk with other signaling pathways such as PI3K/AKT and NF-κB. Targeting JNK/p38 MAPK signaling has shown promise in reversing chemoresistance, with several inhibitors and natural compounds demonstrating potential in preclinical studies. Regulating JNK/p38 MAPK may transform what was once a terminal obstacle into a manageable challenge for OC patients with chemotherapy resistance, ultimately improving survival and quality of life.

Schlagwörter

Stichwörter der Autor:innen

JNKMAPKapoptosisdrug-resistantnatural compoundsovarian cancerp38

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
  • Department of Obstetrics and Gynecology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ma, Y. T., Li, C., Shen, Y., You, W. H., Han, M. X., Mu, Y. F., & Han, F. J. (2025). Mechanisms of the JNK/p38 MAPK signaling pathway in drug resistance in ovarian cancer. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1533352

Vancouver

Ma YT, Li C, Shen Y, You WH, Han MX, Mu YF, et al. Mechanisms of the JNK/p38 MAPK signaling pathway in drug resistance in ovarian cancer. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1533352

BibTeX
@article{Ma2025,
  author = {Ma, Yu-Ting and Li, Chan and Shen, Ying and You, Wan-Hui and Han, Ming-Xuan and Mu, Yi-Fan and Han, Feng-Juan},
  title = {Mechanisms of the JNK/p38 MAPK signaling pathway in drug resistance in ovarian cancer},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1533352}
}
Kostenlos starten →